New biologic IBI311 shows promise for thyroid eye disease in early trial

NCT ID NCT06525506

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II study tested a new biologic drug called IBI311 in 38 people with thyroid eye disease, a condition that causes eye bulging and discomfort. Participants received different doses of the drug to see if it could safely reduce eye protrusion. The trial is completed, and results will help determine if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI311 (a biologic drug given by infusion)
What this could lead to: If successful, this could lead to a new treatment option for thyroid eye disease that reduces eye bulging and improves comfort.
What could go wrong: This is an early Phase II trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or not work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

Innovent Biologics (Suzhou) Co. Ltd

Suzhou, Suzhou, 215123, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.